We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

This study is currently recruiting participants.
Verified July 2016 by Stanford University
Sponsor:
ClinicalTrials.gov Identifier:
NCT00349830
First Posted: July 10, 2006
Last Update Posted: July 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Stanford University
July 5, 2006
July 10, 2006
July 12, 2016
January 2002
January 2022   (Final data collection date for primary outcome measure)
Biomarkers for disease [ Time Frame: Day one ]
Survival analysis and response to anti-cancer therapy
Complete list of historical versions of study NCT00349830 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
blood
Non-Probability Sample
cancer patients
  • Carcinomas (Including Squamous Cell and Adenocarcinoma)
  • Neoplasms
Procedure: blood draw
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
2000
Not Provided
January 2022   (Final data collection date for primary outcome measure)
  1. Age > or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
  2. Prior diagnosis of cancer or suspected of having cancer
  3. Karnofsky performance status of greater than 70
  4. Standard pretreatment evaluation
  5. Signed Stanford University Human Subjects Committee consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
United States
 
 
NCT00349830
VAR0006
77923 ( Other Identifier: Stanford University Alternate IRB Approval Number )
Not Provided
Not Provided
Not Provided
Stanford University
Stanford University
Not Provided
Principal Investigator: Albert Koong Stanford University
Stanford University
July 2016